Barzilai Medical Center is a 617-bed hospital in Ashkelon in southern Israel. The hospital serves a population of 500,000, including a large number of Ethiopian and Russian immigrants, and has more than 100,000 admissions annually.

During the past decade, Barzilai; Rheumatology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Barzilai; Rheumatology" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator and "Pierre Fabre Medicament" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Barzilai; Rheumatology" are "Rheumatoid Arthritis" (2 trials), "BRAF V600E-mutant Metastatic Colorectal Cancer" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Barzilai; Rheumatology" in a lesser frequency.

Most popular intervention types in "Barzilai; Rheumatology" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Irinotecan" (2 trials), "5-Fluorouracil" (1 trials), "Bevacizumab" (1 trials), "Binimetinib" (1 trials) and "Cetuximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Barzilai; Rheumatology" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Barzilai; Rheumatology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Barzilai; Rheumatology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Barzilai; Rheumatology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".